Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 16/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9021759 | 0.99 | HTR4 (0.80) | HTR4 | |
| Hydrochloric Acid SCHEMBL9021925 | 0.98 | HTR4 (0.78) | HTR4 | |
| SCHEMBL9021640 | 0.96 | HTR4 (0.78) | HTR4 | |
| Hydrochloric Acid SCHEMBL9021841 | 0.96 | HTR4 (0.77) | HTR4 | |
| SCHEMBL9021714 | 0.93 | HTR4 (0.75) | HTR4 | |
| SCHEMBL9021618 | 0.93 | HTR4 (0.82) | HTR4 | |
| Hydrochloric Acid SCHEMBL9022385 | 0.92 | HTR4 (0.81) | HTR4 | |
| SCHEMBL9021815 | 0.91 | HTR4 (0.70) | HTR4 | |
| SCHEMBL9021780 | 0.89 | HTR4 (0.82) | HTR4 | |
| Hydrochloric Acid SCHEMBL9022080 | 0.88 | HTR4 (0.81) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-25 | — | — | US | disclosed |
| WO-2021225968-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | HTR4, HTR1A, HTR1D | HTR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.